|
|
Post by akemp3000 on Sept 13, 2019 8:01:58 GMT -5
Long ago, I asked an older mega millionaire client, if there was one piece of advice what would it be? He replied, "Never have to buy or sell anything". You'll be on the losing end of both transactions. IMO, selling Afrezza now before international opportunities increase, pediatric approval kicks in, an improved label and SOC occurs, pipeline success comes into play and there's improved funding to promote Afrezza, would be a horribly timed business decision.
|
|
|
|
Post by sweedee79 on Sept 13, 2019 8:10:19 GMT -5
I am not for selling or leasing out Afrezza at this point.. What would we get for it?
I'm all for Vdex working together with Mnkd to increase scripts and retention as well as holding management accountable, but that is where it ends for me.
|
|
|
|
Post by peppy on Sept 13, 2019 8:14:49 GMT -5
I am not for selling or leasing out Afrezza at this point.. What would we get for it? I'm all for Vdex working together with Mnkd to increase scripts and retention as well as holding management accountable, but that is where it ends for me. agreed. Vdex started the business. Vdex has to work their business model into all the other business models that exist in medicine. That is the same thing MNKD needs to do. It is called health insurance coverage. A very difficult business model in a country where in order to accomplish this you need lots of Mula no matter how good the product is. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 13, 2019 8:17:08 GMT -5
I am not for selling or leasing out Afrezza at this point.. What would we get for it? I'm all for Vdex working together with Mnkd to increase scripts and retention as well as holding management accountable, but that is where it ends for me. It makes no sense for MNKD to partner at this time with Afrezza. Mike is trying to make the asset stronger by getting PEDS Approval (2H20), getting CMS Approval (??/??) which will bring in more insurance coverage, Increasing Scripts, Increasing Revenues, getting more International approvals and possibly enlarge the salesforce. IMO once all of that is achieved then MNKD will look to partner and get a damn good deal. There's very little value in Afrezza right now and Mike would be giving away the ship. Increasing or decreasing the salesforce will be a leading indicator as to their direction. |
|
paul
Researcher
Posts: 134
|
Post by paul on Sept 13, 2019 8:32:12 GMT -5
Both Lilly and Novo have recently cut their insulin prices in half. Is there any likelihood that Mannkind will follow suit?
|
|
|
|
Post by letitride on Sept 13, 2019 8:34:35 GMT -5
I am not for selling or leasing out Afrezza at this point.. What would we get for it? I'm all for Vdex working together with Mnkd to increase scripts and retention as well as holding management accountable, but that is where it ends for me. I don't believe Mannkind can work with VDex per the FDA letter. |
|
|
|
Post by matt on Sept 13, 2019 8:56:32 GMT -5
Both Lilly and Novo have recently cut their insulin prices in half. Is there any likelihood that Mannkind will follow suit? Both Lilly and Novo cut their price but at the same time they cut the rebates paid to the major pharmacy benefit managers. Lilly, in particular, has demonstrated that more than 100% of the price increases seen in recent years were used to obtain a preferred tier status with the PBMs (in short, as the PBMs increased their profit through rebates Lilly actually made less gross profit on the drug). Mannkind was never in that position, partly because Afrezza was never on a preferred tier on any of the major plans so they never paid out a lot of rebates to begin with. There is not a lot of wiggle room in Afrezza pricing since the company barely covers its production cost. If there is any price reduction, don't expect it to be significant and surely not half. |
|
|
|
Post by peppy on Sept 13, 2019 8:57:01 GMT -5
Both Lilly and Novo have recently cut their insulin prices in half. Is there any likelihood that Mannkind will follow suit? prove it. |
|
|
|
Post by sportsrancho on Sept 13, 2019 8:59:58 GMT -5
I am not for selling or leasing out Afrezza at this point.. What would we get for it? I'm all for Vdex working together with Mnkd to increase scripts and retention as well as holding management accountable, but that is where it ends for me. I don't believe Mannkind can work with VDex per the FDA letter. Thats smoke and mirrors they can do a distribution deal with a company that sells to Vdex. Yes agree with you sweedee. And you’d have to ask Spencer how much he thinks Afrezza would lease out for. I have no idea. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 13, 2019 9:08:47 GMT -5
Both Lilly and Novo have recently cut their insulin prices in half. Is there any likelihood that Mannkind will follow suit? I doubt it.......MNKD can't afford to lower their margins at this point. They need to sell the story why Afrezza deserves a premium. |
|
|
|
Post by sweedee79 on Sept 13, 2019 9:17:25 GMT -5
There are ways Mnkd and Vdex could work together I'm sure... Just as Mnkd is getting creative with it's billboards they could find a way if they wanted to.. Retention is a huge problem.
Just because Mnkd received a warning letter from FDA doesn't mean anything .. someone probably filed a complaint.. plenty of people want Afrezza to fail.. their short positions depend on it.
|
|
|
|
Post by compound26 on Sept 13, 2019 9:42:01 GMT -5
I want to make a few comments about the Castagna rejoinder article posted by Spencer Osborn. I really don’t have the time to engage in an extensive back and forth with Mike, so I won’t be posting often. Mikes posts/comments are littered with inaccuracies, many of them intentional. He wants to discredit Vdex and me, and I understand that. We’ve been critical. It’s natural to be hostile one’s critics. Unfortunately, Mike is undermined by his own lack of success in promoting Afrezza. What Vdex has proven is that there is a strategy to make Afrezza the multi-billion-dollar annual drug that it should be. As I posted in another thread, we at Vdex will be sharing more information about that soon. Mike, for all his vaunted successes, hasn’t figured out how to do it. I honestly believe he doesn’t want to see Vdex/HFM succeed because of ego: he didn’t come up with the solution. That’s cynical, but it’s what I believe. But the most important thing people on this board or otherwise should know is that Afrezza really is, as Al Mann said, one the most significant pharmaceutical advancements ever. Let me give some detail here: diabetes is medicine’s great failure. There’s no truer way to say it. Medicine has failed to control this disease. Billions have been spent and billions more will be, but none of the pharmaceutical agents does the job. Even if one gets a patient’s HbA1c down to the ADA-recommended 7%, that’s still not doing the job. Microvascular damage is still occurring at that level. Amputations, blindness, dialysis, etc. are still in the picture. Afrezza changes all that. With Afrezza we can bring BG levels, in many cases, to normal: below 5.7%. With Afrezza we can finally control the disease. And, Afrezza is the ONLY way to do it. Afrezza really is the magic bullet. Imagine the gain to humanity as this product is properly rolled out. Therefore, it is critical to protect this product. We must see this succeed. We need to protect it from the incompetent and the venal. We need to guard it as the crown jewel that it is. Profligate spending by MNKD doesn’t just hurt our stock price; it endangers Afrezza. Better to do nothing than spend wastefully. Everything I see in the Castagna strategy falls into the latter category. Sorry if that offends, but put aside the emotions and examine the situation objectively, and you’re likely to come to the same conclusion. Wow! Bill, while I applaud your efforts in setting up the VDEX clinics and helping making Afrezza a success, what you wrote above is really disappointing. " Mikes posts/comments are littered with inaccuracies, many of them intentional. He wants to discredit Vdex and me, and I understand that. We’ve been critical. It’s natural to be hostile one’s critics. Unfortunately, Mike is undermined by his own lack of success in promoting Afrezza." Thinking about it, it appears to me what you just wrote above applies to what you have done and said to Mike over the last several months very well. Your post above is a good example of that. "What Vdex has proven is that there is a strategy to make Afrezza the multi-billion-dollar annual drug that it should be." When did VDEX prove that? How did VDEX prove that? If VDEX has set up hundreds of clinics and generated thousands of weekly prescripts of Afrezza, I would totally agree this has been proven. Or alternatively, if someone comes up with $500 million to bankroll VDEX because he/she sees the great potential of VDEX, I would also agree this has been proven. However, at this point, I would think you should consider changing your claim to "What Vdex believes is that there is a strategy to make Afrezza the multi-billion-dollar annual drug that it should be." " Profligate spending by MNKD doesn’t just hurt our stock price; it endangers Afrezza. Better to do nothing than spend wastefully. Everything I see in the Castagna strategy falls into the latter category." There are layers upon layers accusations in just this one sentence! Is Mankind's spending profligate? That's debatable. Does it endanger Afrezza? Again that's very much debatable. At least to me, Afrezza now has a much better chance to survive and succeed than a couple years ago after years of "profligate spending my Mannkind" as you would call it. Better to do nothing than spend wastefully?Again, it is debatable whether Mannkind is spending wastefully. But is it better to do nothing? Going back three years to the time right after Sanofi handed back Afrezza to Mannkind, Afrezza's week sales dropped to about $150,000 per week at around mid 2016. Annualized, it is about $7.8 million annual total prescription in dollars (based on Symphony numbers), which translates to an annual net revenue of about $3.5 million. You see, during that period of doing nothing (to Afrezza), Afrezza's sale actually dropped continuingly. Think about it, Dexcom's CGM first got FDA's approval in 2006. If Dexcom has done nothing to promote it, where would it be today? IMHO, in this fiercely competed market, if one does not promote its own product, it will be killed by its competitors pretty easily. Everything I see in the Castagna strategy falls into the latter category. Really, everything? Is it a mistake to conduct the STAT study? The Levin study? To have the packaging fixed? To try out inexpensive means of advertising (such as posters)? To try to have Afrezza approved in overseas (like Brazil)? To have the Afrezza label updated to more accurately reflect its PK/PD profile? ……. |
|
|
|
Post by mango on Sept 13, 2019 10:23:45 GMT -5
I want to make a few comments about the Castagna rejoinder article posted by Spencer Osborn. I really don’t have the time to engage in an extensive back and forth with Mike, so I won’t be posting often. Mikes posts/comments are littered with inaccuracies, many of them intentional. He wants to discredit Vdex and me, and I understand that. We’ve been critical. It’s natural to be hostile one’s critics. Unfortunately, Mike is undermined by his own lack of success in promoting Afrezza. What Vdex has proven is that there is a strategy to make Afrezza the multi-billion-dollar annual drug that it should be. As I posted in another thread, we at Vdex will be sharing more information about that soon. Mike, for all his vaunted successes, hasn’t figured out how to do it. I honestly believe he doesn’t want to see Vdex/HFM succeed because of ego: he didn’t come up with the solution. That’s cynical, but it’s what I believe. But the most important thing people on this board or otherwise should know is that Afrezza really is, as Al Mann said, one the most significant pharmaceutical advancements ever. Let me give some detail here: diabetes is medicine’s great failure. There’s no truer way to say it. Medicine has failed to control this disease. Billions have been spent and billions more will be, but none of the pharmaceutical agents does the job. Even if one gets a patient’s HbA1c down to the ADA-recommended 7%, that’s still not doing the job. Microvascular damage is still occurring at that level. Amputations, blindness, dialysis, etc. are still in the picture. Afrezza changes all that. With Afrezza we can bring BG levels, in many cases, to normal: below 5.7%. With Afrezza we can finally control the disease. And, Afrezza is the ONLY way to do it. Afrezza really is the magic bullet. Imagine the gain to humanity as this product is properly rolled out. Therefore, it is critical to protect this product. We must see this succeed. We need to protect it from the incompetent and the venal. We need to guard it as the crown jewel that it is. Profligate spending by MNKD doesn’t just hurt our stock price; it endangers Afrezza. Better to do nothing than spend wastefully. Everything I see in the Castagna strategy falls into the latter category. Sorry if that offends, but put aside the emotions and examine the situation objectively, and you’re likely to come to the same conclusion. Wow! Bill, while I applaud your efforts in setting up the VDEX clinics and helping making Afrezza a success, what you wrote above is really disappointing. " Mikes posts/comments are littered with inaccuracies, many of them intentional. He wants to discredit Vdex and me, and I understand that. We’ve been critical. It’s natural to be hostile one’s critics. Unfortunately, Mike is undermined by his own lack of success in promoting Afrezza." Thinking about it, it appears to me what you just wrote above applies to what you have done and said to Mike over the last several months very well. Your post above is a good example of that. "What Vdex has proven is that there is a strategy to make Afrezza the multi-billion-dollar annual drug that it should be." When did VDEX prove that? How did VDEX prove that? If VDEX has set up hundreds of clinics and generated thousands of weekly prescripts of Afrezza, I would totally agree this has been proven. Or alternatively, if someone comes up with $500 million to bankroll VDEX because he/she sees the great potential of VDEX, I would also agree this has been proven. However, at this point, I would think you should consider changing your claim to "What Vdex believes is that there is a strategy to make Afrezza the multi-billion-dollar annual drug that it should be." " Profligate spending by MNKD doesn’t just hurt our stock price; it endangers Afrezza. Better to do nothing than spend wastefully. Everything I see in the Castagna strategy falls into the latter category." There are layers upon layers accusations in just this one sentence! Is Mankind's spending profligate? That's debatable. Does it endanger Afrezza? Again that's very much debatable. At least to me, Afrezza now has a much better chance to survive and succeed than a couple years ago after years of "profligate spending my Mannkind" as you would call it. Better to do nothing than spend wastefully?Again, it is debatable whether Mannkind is spending wastefully. But is it better to do nothing? Going back three years to the time right after Sanofi handed back Afrezza to Mannkind, Afrezza's week sales dropped to about $150,000 per week at around mid 2016. Annualized, it is about $7.8 million annual total prescription in dollars (based on Symphony numbers), which translates to an annual net revenue of about $3.5 million. You see, during that period of doing nothing (to Afrezza), Afrezza's sale actually dropped continuingly. Think about it, Dexcom's CGM first got FDA's approval in 2006. If Dexcom has done nothing to promote it, where would it be today? IMHO, in this fiercely competed market, if one does not promote its own product, it will be killed by its competitors pretty easily. Everything I see in the Castagna strategy falls into the latter category. Really, everything? Is it a mistake to conduct the STAT study? The Levin study? To have the packaging fixed? To try out inexpensive means of advertising (such as posters)? To try to have Afrezza approved in overseas (like Brazil)? To have the Afrezza label updated to more accurately reflect its PK/PD profile? ……. 🔨⚰️ (couldn’t find a nail) |
|
|
|
Post by sweedee79 on Sept 13, 2019 10:27:52 GMT -5
I do have some questions for Vdex.. under the current noninferior label and with Mnkds hands tied by FDA how do you propose MC could have done better?
What are your suggestions to Mnkd to change strategy? How could Vdex and Mnkd work together using the Vdex protocol without FDA disaproval?
Help us better understand what you want.
|
|
|
|
Post by uvula on Sept 13, 2019 11:45:24 GMT -5
I do have some questions for Vdex.. under the current noninferior label and with Mnkds hands tied by FDA how do you propose MC could have done better? What are your suggestions to Mnkd to change strategy? How could Vdex and Mnkd work together using the Vdex protocol without FDA disaproval? Help us better understand what you want. The only way for afrezza to become the SOC and the only way for it to make billions is to get a better than noninferior label. The only way to do this is a clinical study and mnkd can't afford to do this. Partnering or selling off afrezza might be the only way to do this. |
|
